Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy (LIVERAIM)

肝硬化和肝癌是常见的，并导致高发病率，生活质量受损，医疗保健系统的主要成本，每年在欧洲造成30万人死亡。主要的病因是肥胖、2型糖尿病和饮酒量增加，这些都在上升。据预测，由于肝病导致的死亡，欧洲的健康预期寿命将在未来30年内下降。肝硬化是在很长一段时间的无症状肝纤维化之后发展起来的，直到患者由于肝硬化或肝癌而出现严重并发症才被发现。目前唯一有效的治疗方法是肝移植，但并不适用于所有患者。如果纤维化被早期检测到，以针对肝脏疾病的过程，那么肝纤维化是可逆的。LIVERAIM项目集中了一个由著名的临床中心和工业合作伙伴组成的团队，包括中小企业，在肝病领域具有丰富的专业知识，目的是设计和验证一个具有生物标志物的筛查平台，用于整个欧洲的人群筛查。其目的是早期识别肝脏疾病并应用个性化治疗干预。将使用来自既往H2020 EU资助队列的40，000例受试者的生物样本库血浆样本，检测大量现有生物标志物的纤维化预测准确性。LIVERAIM将开发一个使用AI的生物标志物筛查平台，用于纤维化的个性化早期诊断，并在来自6个代表性欧盟国家的10万例受试者的RCT中进行验证。该平台将与定制的个性化治疗干预措施相联系，以阻止纤维化进展。通过LIVERAIM，早期诊断和个性化干预可以阻止肝病进展，帮助降低发病率和死亡率以及相关的经济和健康不平等社会负担

Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, causing 300K deaths per year in Europe. Predominant etiological factors are obesity, type2 diabetes, and increased alcohol in take, which are all on the rise. It is predicted that healthy life expectancy will decrease in Europe over the next 30 years because of deaths due to liver disease. Liver cirrhosis develops after a very long period of asymptomatic liver fibrosis, staying undetected until patients develop severe complications due to cirrhosis or liver cancer. Currently the only effective treatment available is liver transplantation which is not applicable to all patients. If fibrosis is detected early, to target the course of liver disease, then liver fibrosis is reversible. The LIVERAIM project concentrates a team of renowned clinical centres and Industrial partners, including SMEs, with great expertise in the field of Liver Disease, the aim being to design and validate a screening platform with biomarkers for population screening to use across Europe. The objective isto identify liver disease early and apply personalized therapeutic interventions. A large number of existing biomarkers will be tested for fibrosis prediction accuracy using biobank plasma samples from 40,000 subjects from previous H2020 EU funded cohorts. LIVERAIM will develop a screening platform with biomarkers using AI for personalized early diagnosis of fibrosis to be validated in a RCT of 100K subjects from 6 representative EU countries. The platform will be linked to tailored, personalized therapeutic interventions to halt fibrosis progression. With LIVERAIM, early diagnosis and personalized intervention can stop liver disease progression, help decrease morbidity and mortality and the associated societal burdens both economic and health inequity